This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Astellas Pharma Gmbh. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Keisuke Tamaki: Innovator in Tetrahydrooxepinopyridine Compounds
Introduction
Keisuke Tamaki is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate nicotinic acetylcholine receptors. His work is aimed at addressing critical health issues, including cognitive impairments and various neurological disorders.
Latest Patents
Tamaki holds a patent for a tetrahydrooxepinopyridine compound. This compound exhibits positive allosteric modulating activity (PAM activity) on the α7 nicotinic acetylcholine receptor. The invention addresses the need for effective agents in preventing or treating conditions such as dementia, cognitive impairment, schizophrenia, Alzheimer's disease, and inflammatory diseases. The findings from his research have the potential to lead to significant advancements in therapeutic options for these conditions.
Career Highlights
Keisuke Tamaki is currently associated with Astellas Pharma GmbH, where he continues to innovate and contribute to the pharmaceutical industry. His expertise in receptor modulation has positioned him as a key figure in the development of new therapeutic agents. With a focus on enhancing cognitive function and treating mental health disorders, Tamaki's work is paving the way for future breakthroughs in medicine.
Collaborations
Tamaki has collaborated with notable colleagues, including Yohei Koganemaru and Satoshi Miyamoto. These partnerships have fostered a collaborative environment that encourages innovative research and development in the field of pharmacology.
Conclusion
Keisuke Tamaki's contributions to the field of pharmacology, particularly through his patent on tetrahydrooxepinopyridine compounds, highlight his commitment to addressing significant health challenges. His work not only advances scientific knowledge but also holds promise for improving the quality of life for individuals affected by cognitive and neurological disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile